Literature DB >> 17388964

Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers.

C Sabbà1, G Pasculli, G M Lenato, P Suppressa, P Lastella, M Memeo, F Dicuonzo, G Guant.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by epistaxis, mucocutaneous telangiectases and visceral arteriovenous malformations (AVMs), particularly in the brain (CAVMs), lungs (PAVMs), liver (HAVMs) and gastrointestinal tract (GI). The identification of a mutated ENG (HHT1) or ALK-1 (HHT2) gene now enables a genotype-phenotype correlation.
OBJECTIVE: To determine the incidence of visceral localizations and evaluate phenotypic differences between ENG and ALK1 mutation carriers.
METHODS: A total of 135 consecutive adult patients were subjected to mutational screening in ENG and ALK1 genes and instrumental tests to detect AVMs, such as chest-abdomen multislice computed tomography (MDCT), brain magnetic resonance imaging and magnetic resonance angiography (MRI/MRA), upper endoscopy, were offered to all patients, independent of presence of clinical symptoms. The 122 patients with identified mutations were enrolled in the study and genotype-phenotype correlations were established.
RESULTS: PAVMs and CAVMs were significantly more frequent in HHT1 (75% vs. 44%, P < 0.0005; 20% vs. 0%, P < 0.002, respectively) and HAVMs in HHT2 (60% vs. 84%, P < 0.01). No age difference was found for PAVMs whereas HAVMs were significantly higher in older patients in both HHT1 and HHT2. Neurological manifestations secondary to CAVMs/PAVMs were found only in HHT1 patients, whereas severe liver involvement was detected only in HHT2. Respiratory symptoms were mainly detected in HHT1.
CONCLUSIONS: Our study evidences a higher visceral involvement in HHT1 and HHT2 compared with previous reports. HHT1 is more frequently associated with congenital AVM malformations, such as CAVMs and PAVMs whereas HHT2 predominantly involves the liver. The ENG gene should be first targeted for mutational screening in the presence of large PAVM in patients < 45 years.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388964     DOI: 10.1111/j.1538-7836.2007.02531.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  60 in total

1.  Basal Ganglia T1 Hyperintensity in Hereditary Hemorrhagic Telangiectasia.

Authors:  A Parvinian; V N Iyer; B S Pannu; D R Apala; C P Wood; W Brinjikji
Journal:  AJNR Am J Neuroradiol       Date:  2017-08-03       Impact factor: 3.825

2.  Embolization of pulmonary arteriovenous malformations using the Amplatzer vascular plug: successful treatment of 69 consecutive patients.

Authors:  Jonathan L Hart; Zaid Aldin; Philip Braude; Claire L Shovlin; James Jackson
Journal:  Eur Radiol       Date:  2010-06-24       Impact factor: 5.315

3.  Integrin β8 Deletion Enhances Vascular Dysplasia and Hemorrhage in the Brain of Adult Alk1 Heterozygous Mice.

Authors:  Li Ma; Fanxia Shen; Kristine Jun; Chen Bao; Robert Kuo; William L Young; Stephen L Nishimura; Hua Su
Journal:  Transl Stroke Res       Date:  2016-06-29       Impact factor: 6.829

4.  Cancer incidence in patients with hereditary hemorrhagic telangiectasia.

Authors:  Christine W Duarte; Adam W Black; F Lee Lucas; Calvin P H Vary
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-16       Impact factor: 4.553

5.  Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease.

Authors:  Kari E Roberts; Steven M Kawut; Michael J Krowka; Robert S Brown; James F Trotter; Vijay Shah; Inga Peter; Hocine Tighiouart; Nandita Mitra; Elizabeth Handorf; James A Knowles; Steven Zacks; Michael B Fallon
Journal:  Gastroenterology       Date:  2010-03-24       Impact factor: 22.682

Review 6.  Angioarchitecture of Hereditary Arteriovenous Malformations.

Authors:  Patricia E Burrows
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

Review 7.  BMP signaling in vascular development and disease.

Authors:  Jonathan W Lowery; Mark P de Caestecker
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-31       Impact factor: 7.638

8.  Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.

Authors:  F S Govani; A Giess; I G Mollet; M E Begbie; M D Jones; L Game; C L Shovlin
Journal:  Mol Syndromol       Date:  2013-04-11

9.  Endoglin is required in Pax3-derived cells for embryonic blood vessel formation.

Authors:  K Young; L T Krebs; E Tweedie; B Conley; M Mancini; H M Arthur; L Liaw; T Gridley; Cph Vary
Journal:  Dev Biol       Date:  2015-10-19       Impact factor: 3.582

10.  Polymorphisms in ACVRL1 and endoglin genes are not associated with sporadic and HHT-related brain AVMs in Dutch patients.

Authors:  Kim Boshuisen; Manon Brundel; Carolien G F de Kovel; Tom G Letteboer; Gabriel J E Rinkel; Cornelis J J Westermann; Helen Kim; Ludmila Pawlikowska; Bobby P C Koeleman; Catharina J M Klijn
Journal:  Transl Stroke Res       Date:  2012-11-29       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.